Charles River Laboratories International, Inc. closed at $332.18 on November 18, 2026, a decline of 1.03% over the prior 24-hour period. The move extended a modest seven-day pullback, with the stock down 3.97% over that stretch.
Despite the recent softness, CRL retained substantial ground gained over the past month. The shares are up 10.59% on a 30-day basis, reflecting a broad recovery that lifted the stock's market capitalization to $16.08 billion.
The divergence between the near-term dip and the stronger monthly performance suggests the stock consolidated after a period of significant appreciation. The one-month advance remains the dominant trend in the data window, even as the past week introduced some selling pressure.
Charles River Laboratories provides contract research and preclinical services to the pharmaceutical and biotechnology industries. Its market value of $16.08 billion positions it among the larger specialized players in the life sciences services sector.



